Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice

In mouse models of melanoma, combining infusions of cancer-killing T cells with Nektar’s experimental immunotherapy drug bempegaldesleukin produced an increased number of T cells. Those cells also lived longer and functioned better than did T cells that were expanded with the protein interleukin 2, UCLA researchers reported.